2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

2:30PM-4:00PM: Abstract Number: 1989

Mechanism of STAT3 Gain-of-Function in a Patient with JIA

Pediatric Rheumatology – Pathogenesis and Genetics

2:30PM-4:00PM: Abstract Number: 1986

Murine Model of Arthritis Flare Identifies Tissue Resident Memory T Cells in Recurrent Synovitis

Pediatric Rheumatology – Pathogenesis and Genetics

2:30PM-4:00PM: Abstract Number: 1997

Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis – Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Safety and Cost Effectiveness

2:30PM-4:00PM: Abstract Number: 1988

Oral Health and Anti-Citrullinated Peptide Antibodies in Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Pathogenesis and Genetics

2:30PM-4:00PM: Abstract Number: 1983

Pain and Sensitization in Women with Aromatase Inhibitor-Associated Arthralgias

Pain – Basic and Clinical Aspects

2:30PM-4:00PM: Abstract Number: 2023

Patient Barriers to Osteoporosis Screening in a Medical Clinic: Why Underserved Patients Who Follow Recommendations for Colonoscopy and Mammography Fail to Get Their DXA Scans

ARHP III: Education and Community Programs

2:30PM-4:00PM: Abstract Number: 1969

Peer Approaches to Lupus Self-Management (PALS): A Novel Lupus Peer Mentorship Intervention

Healthcare Disparities in Rheumatology

2:30PM-4:00PM: Abstract Number: 2017

Performance of Modified Rodnan Skin Score in Early Diffuse Cutaneous Scleroderma-Analysis from 4 International Cohorts

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics II

2:30PM-4:00PM: Abstract Number: 2001

Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Safety and Cost Effectiveness

2:30PM-4:00PM: Abstract Number: 1979

Post-Arthroplasty Pain Trajectories after Total Knee Arthroplasty and Their Association with 6- and 12-Month Pain

Pain – Basic and Clinical Aspects

2:30PM-4:00PM: Abstract Number: 2010

Predictive Factors of Adherence to Treatment in an International Prospective Study of Blood Hydroxychloroquine Levels in SLE Patients with Flares

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 1971

Predictors of Delays to Care and Associated Outcomes in Pediatric Lupus Patients from the Childhood Arthritis and Rheumatology Research Alliance Registry

Healthcare Disparities in Rheumatology

2:30PM-4:00PM: Abstract Number: 2008

Rapamycin Elicits Rapid and Lasting Improvement of Disease Activity through Blocking Pro-Inflammatory T Cell Lineage Specification in Patients with Active SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 1987

Recessive Coding and Regulatory Mutations in FBLIM1 Underlie the Pathogenesis of Sterile Osteomyelitis

Pediatric Rheumatology – Pathogenesis and Genetics

2:30PM-4:00PM: Abstract Number: 1980

Relation of Pain Sensitization to the Evolution from Intermittent to Chronic, Persistent Pain in Knee Osteoarthritis: The Multicenter Osteoarthritis Study

Pain – Basic and Clinical Aspects

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].